Primary Biliary Cholangitis Therapeutics Global Market Report 2026

Description

Primary biliary cholangitis (PBC) therapeutics refer to treatments aimed at managing and slowing the progression of primary biliary cholangitis, a chronic autoimmune liver disease that damages the bile ducts. These therapies work by improving bile flow, reducing inflammation, and slowing liver fibrosis. Their primary purpose is to decrease liver inflammation, enhance bile flow, prevent fibrosis, and delay the onset of liver failure.

The main drug types of PBC therapeutics include ursodeoxycholic acid, obeticholic acid, and others. Ursodeoxycholic acid is a bile acid that helps improve liver function by reducing bile buildup and slowing liver damage, particularly in cholestatic liver diseases such as PBC. These drugs act through various mechanisms of action, including receptor agonism, receptor modulation, enzyme activation, enzyme inhibition, and others. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, drugstores, and online pharmacies, and are used by key end users for human and veterinary applications.

Tariffs have impacted the primary biliary cholangitis therapeutics market by increasing the cost of imported drugs, including ursodeoxycholic acid, obeticholic acid, and investigational therapies. Hospital pharmacies and retail pharmacies in regions like North America and Europe, which rely on imported therapeutics, are most affected. This has led to increased treatment costs and slowed access to newer therapies. On the positive side, tariffs have encouraged local production, investment in domestic drug development, and the creation of cost-effective combination therapies.

The primary biliary cholangitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis therapeutics market statistics, including primary biliary cholangitis therapeutics industry global market size, regional shares, competitors with a primary biliary cholangitis therapeutics market share, detailed primary biliary cholangitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis therapeutics industry. This primary biliary cholangitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary biliary cholangitis therapeutics market size has grown rapidly in recent years. It will grow from $1.01 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to limited treatment options for pbc, growing prevalence of autoimmune liver diseases, increasing liver disease awareness campaigns, reliance on ursodeoxycholic acid monotherapy, expanding hospital infrastructure for liver disease care.

The primary biliary cholangitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to development of obeticholic acid and combination therapies, growth in investigational drugs and pipeline candidates, increasing adoption of receptor agonists and modulators, rising patient awareness and early diagnosis initiatives, expansion of online and retail pharmacy distribution networks. Major trends in the forecast period include rising adoption of ursodeoxycholic acid and obeticholic acid therapies, growth in combination therapies and pipeline drugs, increasing focus on early diagnosis and disease monitoring, expansion of hospital and retail pharmacy distribution channels, rising awareness about autoimmune liver diseases and patient education.

The increasing prevalence of liver diseases is expected to drive the growth of the primary biliary cholangitis therapeutics market in the coming years. Liver diseases comprise conditions that impair liver function, often causing inflammation, scarring, or liver failure. The rise in liver diseases is largely due to increased alcohol consumption, as excessive intake damages liver cells and leads to chronic liver conditions. Primary biliary cholangitis therapeutics help manage liver diseases by targeting bile duct inflammation, slowing disease progression, and preserving liver function. They improve patient outcomes by reducing symptoms, enhancing quality of life, and delaying the need for liver transplantation. For instance, in September 2025, the Centers for Disease Control and Prevention (CDC) reported that chronic liver disease and cirrhosis caused 52,222 deaths in the United States in 2023, making it the ninth leading cause of death. Therefore, the rising prevalence of liver diseases is propelling growth in the primary biliary cholangitis therapeutics market.

Key companies in this market are focusing on developing advanced therapies and securing regulatory approvals, such as peroxisome proliferator-activated receptor (PPAR) agonists, to improve bile acid metabolism and slow disease progression. PPAR agonists activate proteins that regulate genes involved in metabolism, inflammation, and energy balance. For example, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) in adults with an inadequate response to ursodeoxycholic acid (UDCA) or those unable to tolerate UDCA. Livdelzi is an oral, selective PPARδ agonist that regulates genes to reduce liver inflammation, improve bile acid metabolism, and slow PBC progression.

In March 2024, Gilead Sciences Inc. acquired CymaBay Therapeutics Inc. for $4.3 billion. This acquisition strengthens Gilead's liver disease portfolio by adding CymaBay's investigational therapy, seladelpar, a promising treatment for PBC. CymaBay Therapeutics Inc. is a US-based pharmaceutical company specializing in innovative therapies for primary biliary cholangitis.

Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary biliary cholangitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary biliary cholangitis therapeutics market consists of sales of Livdelzi, Iqirvo, Volixibat, fibrates, immunosuppressants, and emerging biologics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Biliary Cholangitis Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses primary biliary cholangitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary biliary cholangitis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary biliary cholangitis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug: Ursodeoxycholic Acid; Obeticholic Acid; Other Drugs
2) By Mechanism Of Action (MOA): Receptor Agonist; Receptor Modulator; Enzyme Activator; Enzyme Inhibitor; Other Mechanisms Of Action
3) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
4) By Use: Human; Veterinary
Subsegments:
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid; Generic Ursodeoxycholic Acid; Combination Therapies With Ursodeoxycholic Acid
2) By Obeticholic Acid: Monotherapy; Combination Therapy; Branded Obeticholic Acid
3) By Other Drugs: Fibrates; Budesonide; Immunosuppressants; Investigational Drugs Or Pipeline Candidates
Companies Mentioned: Novartis AG; Gilead Sciences Inc.; Ipsen Pharma; Intercept Pharmaceuticals; Enanta Pharmaceuticals; Mirum Pharmaceuticals; Calliditas Therapeutics AB; Dr. Falk Pharma GmbH; NGM Biopharmaceuticals Inc.; COUR Pharmaceuticals; HighTide Therapeutics Inc.; Pliant Therapeutics Inc.; Tiziana Life Sciences; Phenex Pharmaceuticals; Synlogic Therapeutics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MPBCT01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Primary Biliary Cholangitis Therapeutics Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Primary Biliary Cholangitis Therapeutics Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Primary Biliary Cholangitis Therapeutics Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Primary Biliary Cholangitis Therapeutics Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
- 4.1.5 Industry 4.0 & Intelligent Manufacturing
4.2. Major Trends
- 4.2.1 Rising Adoption Of Ursodeoxycholic Acid And Obeticholic Acid Therapies
- 4.2.2 Growth In Combination Therapies And Pipeline Drugs
- 4.2.3 Increasing Focus On Early Diagnosis And Disease Monitoring
- 4.2.4 Expansion Of Hospital And Retail Pharmacy Distribution Channels
- 4.2.5 Rising Awareness About Autoimmune Liver Diseases And Patient Education

5. Primary Biliary Cholangitis Therapeutics Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Retail Pharmacies
5.3 Drug Store Pharmacies
5.4 Online Pharmacies
5.5 Liver Disease Specialty Centers

6. Primary Biliary Cholangitis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Primary Biliary Cholangitis Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Primary Biliary Cholangitis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Primary Biliary Cholangitis Therapeutics Market Size, Comparisons And Growth Rate Analysis
7.3. Global Primary Biliary Cholangitis Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Primary Biliary Cholangitis Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Primary Biliary Cholangitis Therapeutics Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Primary Biliary Cholangitis Therapeutics Market Segmentation

9.1. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs
9.2. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action
9.3. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
9.4. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Human, Veterinary
9.5. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Ursodeoxycholic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid
9.6. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monotherapy, Combination Therapy, Branded Obeticholic Acid
9.7. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates

10. Primary Biliary Cholangitis Therapeutics Market Regional And Country Analysis

10.1. Global Primary Biliary Cholangitis Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Primary Biliary Cholangitis Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market

11.1. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Primary Biliary Cholangitis Therapeutics Market

12.1. China Primary Biliary Cholangitis Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Primary Biliary Cholangitis Therapeutics Market

13.1. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Primary Biliary Cholangitis Therapeutics Market

14.1. Japan Primary Biliary Cholangitis Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Primary Biliary Cholangitis Therapeutics Market

15.1. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Primary Biliary Cholangitis Therapeutics Market

16.1. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Primary Biliary Cholangitis Therapeutics Market

17.1. South Korea Primary Biliary Cholangitis Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Primary Biliary Cholangitis Therapeutics Market

18.1. Taiwan Primary Biliary Cholangitis Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Primary Biliary Cholangitis Therapeutics Market

19.1. South East Asia Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Primary Biliary Cholangitis Therapeutics Market

20.1. Western Europe Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Primary Biliary Cholangitis Therapeutics Market

21.1. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Primary Biliary Cholangitis Therapeutics Market

22.1. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Primary Biliary Cholangitis Therapeutics Market

23.1. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Primary Biliary Cholangitis Therapeutics Market

24.1. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Primary Biliary Cholangitis Therapeutics Market

25.1. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Primary Biliary Cholangitis Therapeutics Market

26.1. Eastern Europe Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Primary Biliary Cholangitis Therapeutics Market

27.1. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Primary Biliary Cholangitis Therapeutics Market

28.1. North America Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Primary Biliary Cholangitis Therapeutics Market

29.1. USA Primary Biliary Cholangitis Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Primary Biliary Cholangitis Therapeutics Market

30.1. Canada Primary Biliary Cholangitis Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Primary Biliary Cholangitis Therapeutics Market

31.1. South America Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Primary Biliary Cholangitis Therapeutics Market

32.1. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Primary Biliary Cholangitis Therapeutics Market

33.1. Middle East Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Primary Biliary Cholangitis Therapeutics Market

34.1. Africa Primary Biliary Cholangitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Segmentation By Mechanism Of Action (MOA), Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Primary Biliary Cholangitis Therapeutics Market Regulatory and Investment Landscape

36. Primary Biliary Cholangitis Therapeutics Market Competitive Landscape And Company Profiles

36.1. Primary Biliary Cholangitis Therapeutics Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Primary Biliary Cholangitis Therapeutics Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Primary Biliary Cholangitis Therapeutics Market Company Profiles
- 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Ipsen Pharma Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Intercept Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Enanta Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

37. Primary Biliary Cholangitis Therapeutics Market Other Major And Innovative Companies

Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

38. Global Primary Biliary Cholangitis Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Therapeutics Market

40. Primary Biliary Cholangitis Therapeutics Market High Potential Countries, Segments and Strategies

40.1 Primary Biliary Cholangitis Therapeutics Market In 2030 - Countries Offering Most New Opportunities
40.2 Primary Biliary Cholangitis Therapeutics Market In 2030 - Segments Offering Most New Opportunities
40.3 Primary Biliary Cholangitis Therapeutics Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer